AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27864713
Drug: Uncovered double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncovered double bare metal stent (DBS; S&G Biotech Inc.)
Trial: 27864713
Drug: Uncovered single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncovered single bare metal stent (SBSs; S&G Biotech Inc.)
Trial: 19225067
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or therapy with epidermal growth factor receptor (EGFR) inhibitors
Trial: 19225067
Drug: Docetaxel therapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel therapy every 3 weeks
Trial: 17113676
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (0-15 min before breakfast and dinner)
Trial: 17113676
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RHI) (30-45 min before breakfast and dinner)
Trial: 15161783
Drug: Ragaglitazar 1
RxNorm normalized name: Ragaglitazar
DrugBank: Ragaglitazar (DB06533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragaglitazar 1 mg
Trial: 15161783
Drug: Ragaglitazar 4
RxNorm normalized name: Ragaglitazar
DrugBank: Ragaglitazar (DB06533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragaglitazar 4 mg
Trial: 15161783
Drug: Ragaglitazar 10
RxNorm normalized name: Ragaglitazar
DrugBank: Ragaglitazar (DB06533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragaglitazar 10 mg
Trial: 8001939
Drug: Blood samples
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood samples for measurement of plasma zinc levels; Lavage of the vagina and ectocervix with sterile saline solution for measurement of cervicovaginal zinc levels.
Trial: 3046811
Drug: Theophylline (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5.5 mg/kg administered intravenously)
Trial: 26911396
Drug: 0.5 mg/0.05
RxNorm normalized name: ranibizumab 0.5 mg/0.05 mL INTRAOCULR VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/0.05 ml IVI of bevacizumab (IVB group)
Trial: 26911396
Drug: 1.25 mg/0.05
RxNorm normalized name: bevacizumab 1.25 mg/0.05 mL INTRAOCULR SYRINGE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/0.05 ml IVI of ranibizumab (IVR group)
Trial: 16282244
Drug: rhAngiostatin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhAngiostatin at 15 mg or 60 mg twice daily in combination with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Trial: 16282244
Drug: rhAngiostatin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhAngiostatin at 15 mg or 60 mg twice daily
Trial: 8714363
Drug: Cordaflex 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordaflex 20 mg retard film coated tablets
Trial: 8714363
Drug: Adalat 20
RxNorm normalized name: Adalat 20mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalat 20 mg retard film coated tablets
Trial: 1562025
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment for a mean period of 4 months
Trial: 30012526
Drug: Immunotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy plus stereotactic body radiation therapy (50 Gy/4 fractions)
Trial: 30012526
Drug: Immunotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy plus 45 Gy/15 fractions
Trial: 30012526
Drug: Twice-daily chemoimmunoradiotherapy
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily chemoimmunoradiotherapy (45 Gy in twice-daily fractions)
Trial: 25370504
Drug: Hybrid online
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid online training module for panic disorder (PD) based on cognitive behavioral therapy, consisting of six modules over six weeks
Trial: 17365735
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch 63 mg/day
Trial: 15483079
Drug: Anastrozole (aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (aromatase inhibitor)
Trial: 9793699
Drug: Zolmitriptan 2.5
RxNorm normalized name: zolmitriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 2.5 mg + Diazepam 10 mg
Trial: 9793699
Drug: Zolmitriptan 5
RxNorm normalized name: zolmitriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 5 mg + Diazepam 10 mg
Trial: 8561268
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine alone
Trial: 8561268
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine in combination with pefloxacin
Trial: 8561268
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine alone or in combination with pefloxacin
Trial: 2523210
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of amoxycillin/clavulanic acid (1.2 g Augmentin) at induction of anaesthesia (n = 328)
Trial: 2523210
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of amoxycillin/clavulanic acid (1.2 g Augmentin) along the line of the proposed incision (n = 296)
Trial: 31023758
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of metformin daily
Trial: 25482305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 500 mg of naproxen and 20 mg of esomeprazole (test formulation)
Trial: 25482305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 500 mg of naproxen and 20 mg of esomeprazole (reference formulation)
Trial: 16755394
Drug: Diagnosis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis and treatment related to depression severity
Trial: 12752138
Drug: Narrow-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UVB (311 nm) + calcitriol (twice daily)
Trial: 12752138
Drug: Narrow-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UVB (311 nm) + dithranol (once daily)
Trial: 10863060
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RTH) at a dose of 55 Gy/20 fractions/4 weeks
Trial: 10863060
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RTH) at a dose of 64 Gy/32 fractions/6.5 weeks
Trial: 10863060
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RTH)
Trial: 9197430
Drug: gallopamil 150
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil 150 mg/day
Trial: 9197430
Drug: gallopamil 50
RxNorm normalized name: gallopamil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil 50 mg t.i.d. for 28 days
Trial: 20977356
Drug: n-acetyl-L-carnitine
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-acetyl-L-carnitine
Trial: 11812667
Drug: Metoprolol 50-100
RxNorm normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 50-100 mg b.i.d.
Trial: 11812667
Drug: Xamoterol 100-200
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol 100-200 mg b.i.d.
Trial: 31364979
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg
Trial: 7722712
Drug: High energy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy, high protein supplement (Atole)
Trial: 7722712
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy supplement with no protein (Fresco)
Trial: 1585511
Drug: M-VAC chemotherapy
RxNorm normalized name: M-2698
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-VAC chemotherapy
Trial: 2201047
Drug: Immunological agents
RxNorm normalized name: IMMUNOLOGICAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunological agents
Trial: 2201047
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents or regimens with intensive schedule
Trial: 24389434
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg daily plus pemetrexed 500 mg/m2 intravenously every 3 weeks
Trial: 24389434
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 intravenously every 3 weeks plus pemetrexed 500 mg/m2
Trial: 20810005
Drug: Exposure treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatments (B-ERP and P-ERP)
Trial: 18235425
Drug: Single nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single nasal dose of testosterone; administered in a double-blind, placebo-controlled, crossover manner.
Trial: 18235425
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group); administered in a double-blind, placebo-controlled, crossover manner.
Trial: 18930646
Drug: Salbutamol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (400 mcg)
Trial: 23574529
Drug: Exenatide 5-μg
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide 5-μg twice daily
Trial: 23574529
Drug: Exenatide 10-μg
RxNorm normalized name: exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide 10-μg twice daily
Trial: 22051148
Drug: TAK-875 400
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 400 mg
Trial: 23086138
Drug: TAK-875 100
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 100 mg
Trial: 16457083
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO2), 45 minutes daily for 10 days
Trial: 12859697
Drug: Ibandronate 20
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 20 mg/week
Trial: 10849263
Drug: Interferon-alpha (IFN-α)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-α) 3 or 5 million units (MU) three times weekly (t.i.w.) for 3 months, intensified to daily therapy for those with detectable HCV RNA at 3 months.
Trial: 10849263
Drug: Interferon-alpha (IFN-α)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-α) three times weekly (t.i.w.) for 3 months (control group).
Trial: 8646959
Drug: Anterior sacral
RxNorm normalized name: Boswellia sacra whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior sacral roots stimulator implants
Trial: 6401927
Drug: Norethindrone oral
RxNorm normalized name: norethindrone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone oral contraceptive
Trial: 6401927
Drug: Norgestrel oral
RxNorm normalized name: norgestrel Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel oral contraceptive
Trial: 27799239
Drug: Complementary food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary food supplements and dietary counselling
Trial: 21703973
Drug: Topical budesonide
RxNorm normalized name: budesonide Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical budesonide mouthwash (3 mg/10 mL) applied for 5 or 10 minutes, 2 or 3 times daily
Trial: 19622714
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg qd
Trial: 19622714
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg qd
Trial: 19622714
Drug: Glyburide 5
RxNorm normalized name: glyburide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide 5 mg
Trial: 19622714
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg qd with glyburide
Trial: 15708173
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Cerivastatin + CoQ(10))
Trial: 2690898
Drug: Oral cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclic estrogen/gestagen (n = 20)
Trial: 2690898
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (2000 mg elemental calcium per day) (n = 17)
Trial: 28903941
Drug: Insulin provision
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin provision (IP) therapy
Trial: 28314486
Drug: Insulin sensitizing
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin sensitizing (IS) therapy
Trial: 25283522
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam 1,500 mg
Trial: 25283522
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam 1,500 mg (single infusion)
Trial: 25283522
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam 1,500 mg (repeated infusion)
Trial: 16220495
Drug: Complete-case (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete-case (CC) method
Trial: 15383187
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment (dose titration to achieve LDL-C and non-HDL-C goals)
Trial: 15383187
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment (dose titration)
Trial: 9868840
Drug: Vero-cell rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero-cell rabies vaccine (PVRV, Verorab) according to the 2-1-1 schedule
Trial: 9868840
Drug: Vero-cell rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero-cell rabies vaccine (PVRV) plus equine rabies immunoglobulins (ERIG, 40 IU/kg body weight) according to the 2-1-1 schedule
Trial: 9868840
Drug: Vero-cell rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero-cell rabies vaccine (PVRV) plus human rabies immunoglobulins (HRIG, 20 IU/kg body weight) according to the 2-1-1 schedule
Trial: 8091167
Drug: Omeprazole (OME)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days with N-acetylcysteine (NAC) 2 x 600 mg bid (d 21‐30)
Trial: 8091167
Drug: Omeprazole (OME)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days without N-acetylcysteine (NAC)
Trial: 1130178
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 (2,000 IU daily) for 3 months
Trial: 18041485
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zaleplon
Trial: 21765069
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of IPTp-SP (n = 413)
Trial: 21765069
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of IPTp-SP (n = 401)
Trial: 19015207
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 200 mg plus methotrexate (MTX)
Trial: 19015207
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg plus methotrexate (MTX)
Trial: 16759926
Drug: 25 IU
RxNorm normalized name: Calcium/Vitamin D 200 MG-125 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 IU weekly increments of rFSH
Trial: 16759926
Drug: 50 IU
RxNorm normalized name: Pegaspargase 750 IU/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU weekly increments of rFSH
Trial: 15295244
Drug: Etomidate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (up to 0.3 mg/kg, n = 7)
Trial: 15295244
Drug: Etomidate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (up to 0.4 mg/kg, n = 17)
Trial: 15295244
Drug: Pentobarbital (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (up to 5 mg/kg, n = 33)
Trial: 11699053
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (1,142.0 +/- 79.64 microg/d for at least 12 months)
Trial: 30315901
Drug: Fingolimod (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (0.5, 1.25, or 5 mg/day)
Trial: 30315901
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or intramuscular interferon beta‐1a (IFNβ‐1a IM)
Trial: 21318442
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine injection
Trial: 18496062
Drug: Heparin flushes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin flushes (1:100 dilution)
Trial: 12706129
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition enriched with glutamine (0.7 g kg(‐1)day(‐1))
Trial: 10910450
Drug: Continued MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued MMF treatment (2 g b.i.d.) in group A, n=22
Trial: 10910450
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to AZA treatment (1 mg/kg) in group B, n=26
Trial: 22796985
Drug: Nicotine transdermal
RxNorm normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine transdermal patches
Trial: 1569341
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice a day for 3 days
Trial: 2866073
Drug: MK-208 5
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-208 5 mg
Trial: 2866073
Drug: MK-208 10
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-208 10 mg
Trial: 2866073
Drug: MK-208 20
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-208 20 mg
Trial: 28952607
Drug: 180 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mcg/day of vitamin K2 (menaquinone-7, MK-7)
Trial: 30485516
Drug: Couples calls
RxNorm normalized name: Mosco Corn & Callus Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples calls (CC)
Trial: 22487663
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (morphine, ketorolac, and butylscopolammonium bromide)
Trial: 22487663
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (morphine and ketorolac)
Trial: 11361192
Drug: Ibuprofen 2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 2,400 mg/day
Trial: 7648766
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg (S)-ketamine
Trial: 7648766
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg (S)-ketamine
Trial: 7648766
Drug: 0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/kg (S)-ketamine (control)
Trial: 1009523
Drug: Cyclophosphamide (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (1000 mg/m2 every 3 weeks) iv
Trial: 1009523
Drug: Cyclophosphamide (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (700 mg/m2 every 3 weeks) iv plus CCNU (70 mg/m2 every 6 weeks) orally